<?xml version="1.0" encoding="UTF-8"?>
<p>Scarsi et al., report a 20% improvement in the survival rate at 21 days in patients treated with colchicine compared with the local standard of care [
 <xref rid="B99-molecules-26-00632" ref-type="bibr">99</xref>]. However, Gendelman and co-authors did not detect a potential benefit of colchicine for COVID-19 treatment [
 <xref rid="B100-molecules-26-00632" ref-type="bibr">100</xref>].
</p>
